GlassScriptPhysician profile
Michael Manish Sheth
NPI 1477581684
$1,901.91
in general payments reported to CMS, 2019-2025
27 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $281 · 2021: $399 · 2022: $245 · 2023: $270 · 2024: $139 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $705.80 | 2019-2025 | Relistor |
| Boston Scientific Corporation | $180.82 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $116.69 | 2019 | |
| Medtronic, INC. | $96.83 | 2021-2023 | Intellis Adaptivestim |
| Redhill Biopharma INC. | $74.59 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $68.30 | 2020-2021 | |
| Nevro Corp. | $62.64 | 2024 | Senza |
| Pfizer INC. | $57.99 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $53.51 | 2019 | |
| Scilex Pharmaceuticals INC. | $50.10 | 2019-2022 | |
| Forte Bio-Pharma LLC | $48.36 | 2023 | Prolate, Nalocet |
| Grt US Holding, INC. | $39.23 | 2020 | |
| Mdd US Operations, LLC | $33.93 | 2020 | |
| Abbott Laboratories | $33.67 | 2020-2021 | |
| Depuy Synthes Sales INC. | $32.65 | 2022-2023 | Orthovisc, Monovisc |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $29.29 | 2021 | |
| Sentynl Therapeutics, INC. | $28.80 | 2019 | |
| Bioventus LLC | $26.76 | 2023 | Gelsyn-3 |
| Stryker Corporation | $26.05 | 2019 | |
| Ferring Pharmaceuticals INC. | $24.45 | 2022 | |
| Fidia Pharma USA INC. | $24.44 | 2025 | Hymovis, Triluron |
| Collegium Pharmaceutical, INC. | $23.38 | 2023 | Xtampza |
| Horizon Therapeutics Plc | $23.04 | 2020 | |
| Medtronic USA, INC. | $15.27 | 2019 | |
| Biodelivery Sciences International, INC. | $12.83 | 2019 | |
| Amgen INC. | $12.49 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$159,256.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.